Connect with us
  • Elysium

Neuro rehab technology

Gamified AI mental health platform backed by investment

thymia secures $2.7m to further develop its pioneering monitoring and assessment tech



Thymia co-founders Gabrielle Powell, Emilia Molimpakis and Stefano Goria

A healthtech startup which builds gamified Artificial Intelligence (AI) tools to revolutionise how mental health is monitored and assessed has secured $2.7million to continue to develop its pioneering technology. 

thymia was established by neuroscientist Dr Emilia Molimpakis, who was inspired by her best friend’s struggle with depression whilst at university where doctors and a psychiatrist failed to spot the severity of her condition. 

Currently, doctors use subjective questionnaires and observation to assess cognition – but the system is highly subjective and does not enable clinicians to monitor symptom changes between appointments.

To make mental health assessments more objective, thymia has created AI-powered video games to analyse millions of biomarkers – including patients’ voices, facial expressions, movement and behaviour – and accurately identify symptoms of mental health conditions more easily. 

Its AI models are the only ones globally that combine voice, video and behaviour data in this way. 

The models have been developed using thymia’s proprietary data set of over 1 billion data points collected from over 5000 individuals with depression, generalised anxiety, ADHD and health age-, gender- and language-matched controls: the largest dataset of its kind.

Statistics show that thymia presents up to 84 per cent accuracy in detecting clinical depression and anxiety.

To help further support its development, thymia has secured $2.7million in a seed funding round, led by Kodori Ventures and joined by new and existing investors including Entrepreneur First, Syndicate Room’s Access, Calm/Storm and Form Ventures. Angels include Amanda M Cardinale and Nadav Rosenberg (an early investor in Kheiron Medical).

The raise follows a year where Gabrielle Powell, formerly director of growth at Doctify, joined thymia’s leadership team as COO and co-founder. 

The company also expanded into four new continents, with thymia’s technology now set to be used across the UK, United States, Spain, Brazil, Indonesia and Nigeria, with plans to expand to three more countries this year.

This raise will bring thymia’s total funding to date to $3.5million. thymia will join a number of early-stage mental health innovation companies in the Kodori Ventures portfolio, including Clerkenwell Health.

Dr Molimpakis, co-founder and CEO at thymia, said: “Our mission at thymia from day one has been to make mental health assessments faster, more objective and more reliable. 

“Mental health is complex, but existing assessment methods fail to pick up on the billions of ways different mental health conditions can show up: something I know all too well following my experience with my best friend. 

“As a result, too many people go mis- or undiagnosed; or spiral before anyone realises it’s happening.

“Our technology is revolutionary. By combining cutting-edge neuroscience and ethical, explainable AI, we have built a tool that can help people get an accurate diagnosis and effective treatment plan in place faster than ever before. 

“It’s all about arming clinicians with the very best tools so that they can do the very best by their patients.

“We’re so grateful for the support our investors have shown us so far; and we look forward to this next stage of our journey as we look to optimise and expand our technology and get it in the hands of the people who need it most.”

Alexander Kuznetsov at Kodori Ventures added: “Mental healthcare is one of the most globally pressing issues of our time, and it is essential that we find smarter, innovative ways to help diagnose and treat those struggling with mental health conditions. 

“Kodori Ventures is proud to be backing the team at thymia in their pioneering mental health work. 

“With their recent expansion to four continents, they truly are a global force to be reckoned with in the field of mental health care, and I’m excited to see the impact of their work in the way we diagnose and understand mental health.”